Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09–09 trial - Kapp-Schwoerer, S; Weber, D; Corbacioglu, A (Blood, 2020)
et al.